Skip to main content
Premium Trial:

Request an Annual Quote

ChondroGene, Kaiser Permanente to Conduct Clinical Study for Colon Cancer Dx

NEW YORK, April 28 (GenomeWeb News) - ChondroGene said yesterday that it will partner with Kaiser Permanente of Northern California on a prospective clinical study to evaluate its molecular diagnostic test for colon cancer.


The study will compare the results of the company's ColonSentry blood-based colon cancer test to colonoscopy findings in a group of 600 patients from at-risk and confirmed cancer populations.


The results of the study will be used to advance development of the test, ChondroGene said, and will "allow Kaiser Permanent to evaluate the test in a patient population."


Compared to current stool-based or endoscopic-based screening approaches, "a blood-based test would be more convenient and would likely enhance patient compliance," said T. R. Levin, director of colorectal cancer screening for the Kaiser Permanente Medical Group.


The ColonSentry test is the first commercial diagnostic application of ChondroGene's Sentinel Principle molecular diagnostic technology.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.